Addiction

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

Kratom poses serious addiction risks despite its natural appeal, misleading many into believing it's a safe alternative for pain and withdrawal relief.

The new requirements follow a May Advisory Committee meeting that went over the latest long-term data on opioid risks.

Past month binge drinking rates were greater among females 18-25 years of age than males from 2021-2023, reversing trends seen from 2017-2019.

Scoping review results suggest AUD medications may improve hepatic outcomes in patients with ALD, but limited research exists on such an association.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Liver transplants for alcohol-associated liver disease and alcohol-associated hepatitis have increased, but many centers lack necessary resources for care.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

FDA approves expanded use of buprenorphine extended-release injection for opioid use disorder, adding new injection sites and reducing treatment induction time.

A new study showed sedative, hypnotic, and anxiolytic use disorder diagnoses rose 3- to 5-fold from 2001–2019 among adolescents and young adults.

Mindfulness eased opioid cravings in OUD patients on buprenorphine but showed no added benefit over recovery support for abstinence, substance use, or anxiety.

A study showed age and sex perform better at identifying the risk for opioid use disorder than candidate genetic variants.

A study found a 3.5-fold increased schizophrenia risk in those with hallucinogen-related emergency department visits.

Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.

A new study found using e-cigarettes with partial nicotine reduction was linked to greater puffing time, puff duration, and total inhaled volume than 5% nicotine concentration.

New study finds semaglutide may reduce smoking urge in type 2 diabetes patients, decreasing tobacco use disorder medical encounters by up to 32%.

Depression A new study discovers a dual pathway framework where antidepressants are concomitantly negatively and positively linked to alcohol use.

A new study found claims for services of opioid treatment programs rose among Medicare beneficiaries after Medicare started covering them.

HCPLive spoke with Joshua M. Cohen, MD, MPH, to discuss a post-hoc analysis of a phase 3 study that showed buprenorphine may be effective at reducing fentanyl use.

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.

A new study showed how taking alcohol use disorder medication following an alcohol-related hospitalization discharge was linked to a reduction in return to hospital in 30 days.